ProCE Banner Activity

Phase II Trial of Rusfertide (PTG-300) in Patients With Phlebotomy-Dependent Polycythemia Vera

Slideset Download
Conference Coverage
In this phase II trial in patients with polycythemia vera, rusfertide was associated with rapid, sustained, durable hematocrit control; substantial reduction in phlebotomy; and improved patient-reported outcomes.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation